Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: Impact on mortality

Annals of Oncology

Volumn 21, Issue SUPPL.3, 2010, Pages

  Larranaga N ^a,b   Galceran, J ^c   Ardanaz, E ^b,d   Franch, P ^e   Navarro, C ^b,f   Sanchez M J ^b,g   Pastor Barriuso, R ^b,h   Martos, C ⁱ   Rodriguez L ^j   Vilardell, L ^k   Chico, M ^l   Mateos, A ^l   Fernandez D ^m   Linares, C ⁿ  

^a Basque Country Regional Authority   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^d INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^e Mallorca Cancer Registry   (Spain)

^f Health Authority   (Spain)

^g ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^h CARLOS III INSTITUTE OF HEALTH   (Spain)

ⁱ INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^j Health and Medical Services Authority   (Spain)

^k DEPARTMENT OF HEALTH   (Spain)

^l Health and Social Welfare Authority   (Spain)

^m Canary Islands Cancer Registry   (Spain)

ⁿ INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Incidence; Mortality; Prostate neoplasms; PSA; Spain; Trends

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHILD; CLINICAL INDICATOR; CONTROLLED STUDY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SCHOOL CHILD; SPAIN; TREND STUDY; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; INCIDENCE; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; TIME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPAIN; TIME FACTORS;

EID: 79952117635     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq087     Document Type: Article

References (51)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon, France: IARC 2004.
2. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2008.
3. Parkin DM, Whelan P, Ferlay J, Storm H. Cancer Incidence in Five Continents, Vol. I-VIII. IARC Cancer Base No. 7. Lyon, France: IARC 2005.
4. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
5. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents. Vol IX. [IX]. 2007. (IARC Scientific Publications No. 160). Lyon, France: IARC 2005.
6. Quaglia A, Parodi S, Grosclaude P et al. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe. An analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer 2003; 39: 654-665.
7. Cayuela A, Rodríguez-Domínguez S, Vigil-Martín E, Barrero-Candau BR. Cambios recientes en la mortalidad por cáncer de pró stata en España: estudio de tendencias en el periodo 1991-2005. Actas Urol Esp 2008; 32: 184-189.
8. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991; 83: 551-557.
9. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol Rev 2001; 23: 19-23.
10. Allen NE, Key TJ, Appleby PN et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008; 98: 1574-1581.
11. Crowe FL, Key TJ, Appleby PN et al. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2008; 87: 1405-1413.
12. Pischon T, Boeing H, Weikert S et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008; 17: 3252-3261.
13. Weiss JM, Huang WY, Rinaldi S et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008; 122: 2345-2350.
14. Potosky AL, Kessler L, Gridley G et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990; 82: 1624-1628.
15. Merrill RM, Feuer EJ, Warren JL et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999; 150: 848-860.
16. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-552.
17. Pollán M, Pastor-Barriuso R, Ardanaz E et al. Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst 2009; 101: 1584-1591.
18. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-351.
19. Pastor-Barriuso R, Guallar E, Coresh J. Transition models for change-point estimation in logistic regression. Stat Med 2003; 22: 1141-1162.
20. Osmond C, Gardner MJ. Age, period and cohort models applied to cancer mortality rates. Stat Med 1982; 1: 245-259.
21. Decarli A, La Vecchia C. Age, period and cohort models: review of knowledge and implementation in GLIM. Riv Stat Applicata 1987; 20: 397-410.
22. Hankey BF, Feuer EJ, Clegg LX et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-1024.
23. Collin SM, Martin RM, Metcalfe C et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445-452.
24. Smith DP, Supramaniam R, Marshall VR, Armstrong BK. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust 2008; 189: 315-318.
25. Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 2000; 85: 463-472.
26. Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 2007; 175: 1-8.
27. Ministerio de Sanidad y Política Social. Encuesta Nacional de Salud de España. 2009 http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/home.htm (1 October 2009, date last accessed).
28. Helgesen F, Holmberg L, Johansson JE et al. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 1996; 88: 1216-1221.
29. Levy I. Trends in incidence and mortality of prostate cancer in Canada. Chronic Dis Can 1995; 16 (1 Suppl): http://www.phac-aspc.gc.ca/publicat/cdic-mcc/16-1sup/c_e.html (4 June 2008, date last accessed).
30. Kvale R, Auvinen A, Adami HO et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007; 99: 1881-1887.
31. Hussain S, Gunnell D, Donovan J et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int 2008; 101: 547-555.
32. Pashayan N, Powles J, Brown C, Duffy SW. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Cancer 2006; 95: 401-405.
33. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-990.
34. Etzioni R, Legler JM, Feuer EJ et al. Cancer surveillance series: interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1033-1039.
35. Stamey TA, Caldwell M, McNeal JE et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297-1301.
36. Pashayan N, Powles J, Brown C, Duffy SW. Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing. Br J Cancer 2006; 95: 398-400.
37. Levy IG, Iscoe NA, Klotz LH. Prostate cancer: 1. The descriptive epidemiology in Canada. CMAJ 1998; 159: 509-513.
38. Oliva G, Allapuz A, Kotzeva A et al. Variaciones en hospitalizaciones por cirugía oncoló gica en el Sistema Nacional de Salud 2009: http://www.atlasvpm.org/avpm/nodoUser.navegar.do?idObjeto=161&hijos= 6&indice=1&subindice=0&nieto=15&marcado=1 (1 October 2009, date last accessed).
39. Bouchardy C, Fioretta G, Rapiti E et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421-429.
40. Cayuela A, Rodríguez-Domínguez S, Vigil-Martín E et al. Tendencias divergentes en la mortalidad por cáncer de pró stata en la Comunidad Autonoma de Andalucía. Actas Urol Esp 1975-2004; 2007(31): 92-97.
41. Vutuc C, Waldhoer T, Lunglmayr G et al. PSA testing in Austria: induced morbidity and saved mortality. Eur J Cancer Prev 2009; 18: 377-380.
42. Andren O, Garmo H, Mucci L et al. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009; 100: 170-173.
43. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25: 3-9.
44. Flamand V, Zini L, Salleron J et al. Enquête observationnelle sur les variations d'incidence par stade des cancers de la prostate dans la région Nord-Pas-de-Calais entre 1998 et 2004. Prog Urol 2008; 18: 53-59.
45. Vutuc C, Waldhoer T, Madersbacher S et al. Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev 2001; 10: 425-428.
46. Pashayan N, Duffy SW, Pharoah P et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009; 100: 1198-1204.
47. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
48. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-1329.
49. Coleman MP, Quaresma M, Berrino F et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756.
50. Istituto Superiore di Sanità(Italy). Survival of Cancer Patients in Europe (EUROCARE) 2009. http://www.eurocare.it/Home/tabid/36/Default.aspx (1 June 2009, date last accessed).
51. Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 2004; 15: 237-241.